GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Gross Profit

Fortress Biotech (FRA:CNB1) Gross Profit : €53.91 Mil (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Gross Profit?

Fortress Biotech's gross profit for the three months ended in Mar. 2024 was €5.72 Mil. Fortress Biotech's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was €53.91 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Fortress Biotech's gross profit for the three months ended in Mar. 2024 was €5.72 Mil. Fortress Biotech's Revenue for the three months ended in Mar. 2024 was €11.99 Mil. Therefore, Fortress Biotech's Gross Margin % for the quarter that ended in Mar. 2024 was 47.69%.

Fortress Biotech had a gross margin of 47.69% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Fortress Biotech was 78.79%. The lowest was 31.13%. And the median was 68.22%.

Warning Sign:

Fortress Biotech Inc gross margin has been in long-term decline. The average rate of decline per year is -3.9%.


Fortress Biotech Gross Profit Historical Data

The historical data trend for Fortress Biotech's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Gross Profit Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.49 25.49 32.49 42.45 53.05

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.59 8.88 26.54 12.78 5.72

Competitive Comparison of Fortress Biotech's Gross Profit

For the Biotechnology subindustry, Fortress Biotech's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Gross Profit distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Gross Profit falls into.



Fortress Biotech Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Fortress Biotech's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=77.498 - 24.447
=53.05

Fortress Biotech's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=11.988 - 6.271
=5.72

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €53.91 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Fortress Biotech's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=5.72 / 11.988
=47.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Fortress Biotech  (FRA:CNB1) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Fortress Biotech had a gross margin of 47.69% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Fortress Biotech Gross Profit Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines